Management healthcare consultancy opens new offices in New York and London
The expansion will enable Putnam Associates to access the European market and to offer more localised support to its clients.
Putnam Associates, a US-based strategic management healthcare consultancy and part of UDG Healthcare, has recently opened two new offices in New York and London.
Headquartered in Boston with an office in San Francisco, Putnam employs more than 130 people and offers specialist consultancy services across the product life cycle to life science organisations with particular strengths in product commercialisation, market access strategy, and medical and scientific affairs.
The consultancy is opening new offices in Chiswick, London and in Midtown Manhattan, New York as part of its strategy to increase its global footprint and offer more localised support to its clients.
Putnam will also tap into the talent pools of both cities and plans to recruit experienced associates and management consultants across a number of roles in both locations.
Commenting on the new offices, Remco op den Kelder, CEO said: “Being part of UDG has created a number of opportunities for Putnam to leverage the infrastructure and resources of a global leader in life science services in a number of key regions.
“Our new office in London is a huge opportunity for us to access the European market.”
Putnam significantly strengthened the breadth of services offered by Ashfield’s Advisory division when it was acquired in early 2019. The consultancy added capabilities and scale to the existing advisory pillar, in particular in the global pricing, value and access area.
Op den Kelder continued: “Our new locations will also enable us to add to our talented teams as we look to recruit at every level, from senior leaders and experienced management consultants to graduates looking to start a career in the sector.
“The life sciences is an exciting industry to be a part of, the work we do is impactful and we work in a very dynamic environment so we’re always searching for top performers to join us.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.